This week's news includes Danaher, BGI, Mobadiag, and Sygnis.
IDT will operate as a standalone company within Danaher's Life Sciences segment after the close of the deal, which is expected to occur in mid-2018.
In Life Sciences, CEO Thomas Joyce noted a strong performance by Beckman Coulter, while in Diagnostics, he said Cepheid grew 25 percent year over year.
Some of the biggest players in the life science tools and diagnostics industries including Danaher, Agilent, and Hologic presented on day two of the conference, discussing plans for 2018.
The investment bank said that Danaher, Illumina, Qiagen, and Thermo Fisher Scientific were its top picks.
The company said that EPS for next year is anticipated to be between $3.50 and $3.60. On an adjusted basis, EPS is expected in the range of $4.25 to $4.35.
IDBS provides enterprise solutions for scientific data management, analytics, and modeling including the E-WorkBook Suite.
The firm beat the consensus Wall Street estimates on the top and bottom lines as the diagnostics segment saw revenues grow 20 percent year over year.
The company has shut down the Veris molecular diagnostics product line, which Beckman Coulter spent years developing, as a result of its acquisition of Cepheid.
The firm's European subsidiary is offering the new senior notes to repay, in part, all outstanding aggregate principal amounts on senior notes due later this month.
Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing.
Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.
Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports.
In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.